Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 3 1

Status

Completed 9Terminated 5Recruiting 5Active not recruiting 2

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 5Lymphoid 3Gastrointestinal 3Thoracic 2Head & Neck 2Dermatologic 2Other hematologic neoplasm 1Myeloid 1Gynecologic 1Genitourinary 1CNS 1

Conditions

Breast Neoplasms 1131Triple Negative Breast Neoplasms 147Neoplasm Metastasis 99Carcinoma, Non-Small-Cell Lung 85Ovarian Neoplasms 81Neoplasms 75Lung Neoplasms 64Colorectal Neoplasms 60Melanoma 59Stomach Neoplasms 44Pancreatic Neoplasms 43Breast Neoplasms, Male 43Prostatic Neoplasms 42Carcinoma, Renal Cell 37Squamous Cell Carcinoma of Head and Neck 34Sarcoma 30Colonic Neoplasms 29Endometrial Neoplasms 28Head and Neck Neoplasms 26Brain Neoplasms 24Urinary Bladder Neoplasms 22Esophageal Neoplasms 21Carcinoma, Ovarian Epithelial 21Carcinoma, Intraductal, Noninfiltrating 21Lymphoma, Non-Hodgkin 19Recurrence 18Uterine Cervical Neoplasms 17Inflammatory Breast Neoplasms 17Breast Carcinoma In Situ 17Multiple Myeloma 16

Interventions

Fulvestrant 3Alpelisib 2volagidemab 1olaparib 1dapagliflozin 1NVP-BKM120 1Drug Therapy 1CYH33 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Terminated × Hereditary Sensory and Autonomic Neuropathies × Breast × Clear all
NCT04899349 2024-10-09

EPIK-B4

Novartis

Phase 2 Terminated
2 enrolled 8 charts
Breast

Breast Neoplasms, Hyperglycemia, Hereditary Sensory and Autonomic Neuropathies

NCT04586335 2024-03-21

Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.

Haihe Biopharma Co., Ltd.

Phase 1 Terminated
24 enrolled
BreastGenitourinaryGynecologic

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

NCT03386162 2022-11-28

SAFIR-PI3K

UNICANCER

Phase 2 Terminated
31 enrolled
Breast

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

NCT04330625 2022-11-08

Glucagon Receptor Inhibition to Enable Breast Cancer Patients to Benefit From PI3K Inhibitor Therapy (REMD-477)

Duke University

Phase 1 Terminated
1 enrolled
Breast

Breast Neoplasms, Hyperglycemia, Hereditary Sensory and Autonomic Neuropathies

NCT01633060 2019-01-30

BELLE-3

Novartis

Phase 3 Terminated
432 enrolled 20 charts
Breast

Breast Neoplasms, Neoplasm Metastasis, Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡